BR112013013869A2 - método para diagnóstico de um carcinoma e usos do mesmo - Google Patents

método para diagnóstico de um carcinoma e usos do mesmo

Info

Publication number
BR112013013869A2
BR112013013869A2 BR112013013869A BR112013013869A BR112013013869A2 BR 112013013869 A2 BR112013013869 A2 BR 112013013869A2 BR 112013013869 A BR112013013869 A BR 112013013869A BR 112013013869 A BR112013013869 A BR 112013013869A BR 112013013869 A2 BR112013013869 A2 BR 112013013869A2
Authority
BR
Brazil
Prior art keywords
carcinoma
diagnosing
stem cells
immunofluorescence
immunohistochemistry
Prior art date
Application number
BR112013013869A
Other languages
English (en)
Inventor
Alfredo Di Leo
Donato Altomare
Filippo Bastia
Maria Teresa Rotelli
Michele Barone
Original Assignee
Thd Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thd Spa filed Critical Thd Spa
Publication of BR112013013869A2 publication Critical patent/BR112013013869A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)

Abstract

método para diagnóstico de um carcinoma e usos do mesmo a presente invenção refere-se a um método para o diagnóstico de um carcinoma ou uma doença residual associada ao mesmo, ou para o prognóstico de um carcinoma, ou para monitorar a eficácia de uma terapia antitumoral direcionada contra um carcinoma, ou para monitorar o acompanhamento de um indivíduo afetado por um carcinoma, em particular colorretal, carcinoma do estômago, carcinoma mamário, carcinoma pulmonar ou carcinoma da próstata, carcinoma do fígado, carcinoma do ovário, carcinoma do rim, carcinoma da tireoide, carcinoma da bexiga ou carcinoma do pâncreas. o método da invenção consiste em colocar células-tronco adultas em contato com uma amostra de um hemoderivado do indivíduo a ser analisado e em verificar a expressão de pelo menos um marcador epitelial nas células-tronco através de imunofluorescência, imuno-histoquímica, elisa ou rt-pcr.
BR112013013869A 2010-12-06 2010-12-06 método para diagnóstico de um carcinoma e usos do mesmo BR112013013869A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2010/000484 WO2012077139A1 (en) 2010-12-06 2010-12-06 Method for the diagnosis of a carcinoma and uses thereof

Publications (1)

Publication Number Publication Date
BR112013013869A2 true BR112013013869A2 (pt) 2016-12-06

Family

ID=44146327

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013869A BR112013013869A2 (pt) 2010-12-06 2010-12-06 método para diagnóstico de um carcinoma e usos do mesmo

Country Status (15)

Country Link
US (1) US9347953B2 (pt)
EP (1) EP2649445B1 (pt)
JP (1) JP6018074B2 (pt)
KR (1) KR20140034124A (pt)
CN (1) CN103384824B (pt)
AR (1) AR084163A1 (pt)
AU (1) AU2010365277B2 (pt)
BR (1) BR112013013869A2 (pt)
CA (1) CA2819390A1 (pt)
HK (1) HK1186247A1 (pt)
IL (1) IL226570A (pt)
RU (1) RU2013126024A (pt)
SA (1) SA111330026B1 (pt)
SG (1) SG191028A1 (pt)
WO (1) WO2012077139A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014032728A2 (pt) 2012-06-27 2017-11-28 Berg Llc uso de marcadores no diagnóstico e tratamento de câncer de próstata
SG11201704660YA (en) 2014-12-08 2017-07-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
CN106093432A (zh) * 2016-06-13 2016-11-09 厦门大学 基于联合检测fgf1、fgf10和il6的乳腺癌诊断试剂盒
KR101847435B1 (ko) 2016-09-30 2018-04-10 부경대학교 산학협력단 부갑상선 실시간 이미징 장치
CN106478820A (zh) * 2016-10-10 2017-03-08 米度（南京）生物技术有限公司 一种肝癌pet诊断示踪剂及其制备方法与用途
CA3042382A1 (en) * 2016-11-02 2018-05-11 Aal Scientifics, Inc. Non-mesenchymal human lung stem cells and methods of their use for treating respiratory diseases
CN106944163A (zh) * 2017-01-24 2017-07-14 瑞汉智芯医疗科技(嘉善)有限公司 一种针对尿路上皮癌的尿脱落肿瘤细胞的免疫荧光染色技术

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4307552B2 (ja) 1996-03-15 2009-08-05 ミューニン コーポレイション 細胞外マトリックスシグナリング分子
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
DK1351707T3 (da) * 2001-01-09 2011-07-11 Baylor Res Inst Fremgangsmåder til behandling af autoimmunsygdomme hos et individ og in vitro-diagnostiske analyser
US7150990B2 (en) * 2002-03-06 2006-12-19 Reprocell, Inc. Self-renewing pluripotent hepatic stem cells
WO2004024957A2 (en) * 2002-09-12 2004-03-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for detection of micro-metastasis
GB0320877D0 (en) 2003-09-05 2003-10-08 Celltech R&D Ltd A protein involved in carcinoma
ITPD20030264A1 (it) * 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
US20050233449A1 (en) * 2004-04-16 2005-10-20 Kuan-Der Lee Simple and rapid derivation of functional hepatocytes from human bone marrow-derived mesenchymal stem cells
CA2579764A1 (en) * 2004-08-10 2006-02-23 Institute For Multiple Myeloma And Bone Cancer Research Methods of regulating differentiation and treating of multiple myeloma
WO2007089945A2 (en) 2006-02-02 2007-08-09 The Trustees Of Columbia University In The City Of New York Treating diseases by targeting silt3
RU2489720C2 (ru) * 2007-02-27 2013-08-10 Сентоклон Интернэшнл Аб Мультиплексная детекция опухолевых клеток с использованием панели агентов, связывающихся с внеклеточными маркерами
EP2333047A1 (en) * 2009-12-09 2011-06-15 Fresenius Medical Care Deutschland GmbH Adult stem cell derived conditioned medium and/or adult stem cells for use in the therapeutic treatment of a tumor disease

Also Published As

Publication number Publication date
CN103384824B (zh) 2016-02-03
CN103384824A (zh) 2013-11-06
EP2649445A1 (en) 2013-10-16
HK1186247A1 (en) 2014-03-07
WO2012077139A1 (en) 2012-06-14
CA2819390A1 (en) 2012-06-14
RU2013126024A (ru) 2015-01-20
KR20140034124A (ko) 2014-03-19
JP6018074B2 (ja) 2016-11-02
US9347953B2 (en) 2016-05-24
IL226570A (en) 2016-05-31
SG191028A1 (en) 2013-07-31
AU2010365277A1 (en) 2013-06-13
US20130316361A1 (en) 2013-11-28
SA111330026B1 (ar) 2015-04-06
WO2012077139A8 (en) 2012-08-16
AR084163A1 (es) 2013-04-24
AU2010365277B2 (en) 2017-01-05
JP2014500026A (ja) 2014-01-09
EP2649445B1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
BR112013013869A2 (pt) método para diagnóstico de um carcinoma e usos do mesmo
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
EP3744859A3 (en) Microrna biomarker for the diagnosis of gastric cancer
EA201500219A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
EA201492055A1 (ru) ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
PH12014501918A1 (en) Novel fgfr3 fusion
BR112013004673A2 (pt) biomarcadores e métodos de tratamento.
Kataria et al. Withania somnifera water extract as a potential candidate for differentiation based therapy of human neuroblastomas
BR112014030750A2 (pt) Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
MX2013011041A (es) Capa de difusion mejorada para sensor enzimatico in vivo.
NZ630026A (en) Inhibition of the glycine cleavage system for treatment of cancer
MX339427B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico.
MX343801B (es) Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer de mama.
MX2017009998A (es) Biomarcadores para cancer pancreatico.
WO2013025952A3 (en) Methods and compositions for the treatment and diagnosis of breast cancer
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
WO2011094759A3 (en) Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2012151390A3 (en) A therapeutic and diagnostic target gene in acute myeloid leukemia
Layunta et al. NOD2 modulates serotonin transporter and interacts with TLR2 and TLR4 in intestinal epithelial cells
AU2018275891A1 (en) Articles of manufacture and methods related to toxicity associated with cell therapy
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
MX2020006660A (es) Biomarcadores de tolerancia inmunitaria inducida por metotrexato.
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
MX2017009857A (es) Isoformas delta133p53beta y delta133p53gamma son biomarcadores de celulas madre cancerosas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.